After second dose, Pfizer’s efficacy declined from 96% down to 84%
The Pfizer-BioNTech vaccine’s efficacy against SARS-CoV-2 peaked at 96.2% at seven days to two months after the second dose and…
The Pfizer-BioNTech vaccine’s efficacy against SARS-CoV-2 peaked at 96.2% at seven days to two months after the second dose and…
Monoclonal Antibody provides guidance for the treatment of Coovid-19 as advance investigations uncover that monoclonal immune response (CR3022) is extremely…
Currently, phase 2, 3 clinical trials of the Oxford sponsor vaccine is ongoing in United Kingdom By Reuters The vaccine…
To avail the opportunities that After-Covid19 world offers in the field of learning and development, we need to be quickly…
In continuation of its COVID-19 relief efforts, Telenor Pakistan has extended its support for food distributionin partnership with Pakistan Red…